WAM
REGN icon

Wolverine Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Wolverine Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-50
Closed -$1.11M – 1556
2015
Q4 		$1.11M Hold
50
– – 0.02% 455
2015
Q3 		$746K Hold
50
– – 0.02% 585
2015
Q2 		$974K Hold
50
– – 0.02% 477
2015
Q1 		$725K Sell
50
-100
-67% -$42.4K 0.01% 517
2014
Q4 		$1.89M Hold
150
– – 0.04% 307
2014
Q3 		$1.24M Hold
150
– – 0.03% 414
2014
Q2 		$539K Buy
150
+50
+50% +$14.8K 0.01% 578
2014
Q1 		$571K Sell
100
-443
-82% -$136K 0.01% 562
2013
Q4 		$615K Sell
543
-259
-32% -$74.5K 0.01% 701
2013
Q3 		$2.93M Buy
802
+100
+14% +$26.3K 0.07% 242
2013
Q2 		$637K Buy
+702
New +$163K 0.02% 636

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Wolverine Asset Management's REGN Position: Q3 2021 in Review

Wolverine Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2021, closing a stake of 110 shares — an estimated $61K sold.

Wolverine Asset Management first reported a position in REGN in Q2 2015 and held it in 10 quarters. The position peaked at $23.6M in Q2 2015. 1,017 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

  • Wolverine Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Wolverine Asset Management sold 110 Regeneron Pharmaceuticals shares in Q3 2021, an estimated $61K.
  • Wolverine Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 10 quarters.
  • Wolverine Asset Management's Regeneron Pharmaceuticals position peaked at $23.6M in Q2 2015.
  • 1,017 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on Wolverine Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.